VEGF kinase inhibitors: how do they cause hypertension?
VEGF kinase inhibitors: how do they cause hypertension?
复制标题
DOI：
10.1152/ajpregu.90502.2008
复制
发表时间：
2009-07-01
影响因子：
2.8
通讯作者：
Bhargava, Pankaj
中科院分区：
文献类型：
--
作者：
Bhargava, Pankaj
Bhargava P. VEGF激酶抑制剂：它们如何引起高血压？Am J Physiol Regul Integr Comp Physiol 297：R1-R5，2009.首次发表于2009年5月13日; doi：10.1152/ajpregu.90502.2008。-新血管生成是一个关键的现象，使肿瘤的生长和转移，和新血管生成的抑制剂最近已被添加到可用于临床使用的抗癌疗法的医疗设备。通过血管内皮生长因子（VEGF）途径的失调的信号传导已经被认为是肿瘤中新血管生成的关键介质。通过VEGF途径阻断信号传导的药物在临床前模型中显示出肿瘤缩小，因此被开发为用于人类的抗癌疗法。VEGF激酶抑制剂被用于治疗各种癌症，最近的研究表明，患者可能需要长期使用这些药物治疗。高血压已成为与阻断VEGF通路信号传导的药物相关的常见副作用。深入了解高血压的潜在机制对于制定适当的治疗策略来治疗VEGF激酶抑制剂相关的高血压至关重要。最近的几项研究已经推进了我们对VEGF激酶抑制剂相关的高血压病理生理学的理解，并将成为本次审查的主题。
Bhargava P. VEGF kinase inhibitors: how do they cause hypertension?. Am J Physiol Regul Integr Comp Physiol 297: R1-R5, 2009. First published May 13, 2009; doi:10.1152/ajpregu.90502.2008.-Neoangiogenesis is a critical phenomenon enabling the growth and metastasis of tumors, and inhibitors of neoangiogenesis have been recently added to the armamentarium of anticancer therapies available for clinical use. Dysregulated signaling through the vascular endothelial growth factor ( VEGF) pathway has been implicated as a key mediator of neoangiogenesis in tumors. Agents that block signaling through the VEGF pathway demonstrated tumor shrinkage in preclinical models and were therefore developed as anticancer therapies for use in humans. VEGF kinase inhibitors are being used in the treatment of a wide variety of cancers, and recent studies have shown that patients will likely require long-term treatment with these agents. Hypertension has emerged as a frequent side effect associated with agents that block signaling through the VEGF pathway. A thorough understanding of the mechanisms underlying hypertension is crucial to developing appropriate therapeutic strategies for treating hypertension associated with VEGF kinase inhibitors. Several recent studies have advanced our understanding of the pathophysiology of hypertension associated with VEGF kinase inhibitors and will be the subject of this review.